PDF(Pubmed)
Abstract：
UNASSIGNED: DNA ploidy (P), stroma fraction (S), and nucleotyping (N) collectively known as PSN, have proven prognostic accuracy in stage II colorectal cancer (CRC). However, few studies have reported on the prognostic value of the PSN panel in stage III colon cancer patients receiving capecitabine and oxaliplatin adjuvant chemotherapy.
UNASSIGNED: This study aimed to validate PSN\'s prognostic impact on stage III colon cancer, identifying candidates for optimized adjuvant chemotherapy duration.
UNASSIGNED: A retrospective analysis was conducted on a cohort of stage III colon cancer patients from April 2008 to June 2020.
UNASSIGNED: Postoperative pathological samples from stage III colon cancer patients who underwent radical surgery and postoperative adjuvant chemotherapy at Sun Yat-sen University Cancer Center were retrospectively collected. Automated digital imaging assessed PSN, categorizing risk groups. Kaplan-Meier, Cox regression, and time-dependent receiver operating characteristic analysis compared model validity.
UNASSIGNED: Significant differences in 5-year disease-free survival (DFS) and overall survival (OS) were noted among PSN-based low-, moderate-, and high-risk groups (DFS: 92.10% versus 83.62% versus 79.80%, p = 0.029; OS: 96.69% versus 93.99% versus 90.12%, p = 0.016). PSN emerged as an independent prognostic factor for DFS [hazard ratio (HR) = 1.409, 95% confidence interval (CI): 1.002-1.981, p = 0.049] and OS (HR = 1.720, 95% CI: 1.127-2.624, p = 0.012). The PSN model, incorporating perineural invasion and tumor location, displayed superior area under the curve for 5-year (0.692 versus 0.553, p = 0.020) and 10-year (0.694 versus 0.532, p = 0.006) DFS than TNM stage. In the PSN high-risk group, completing eight cycles of adjuvant chemotherapy significantly improved 5-year DFS and OS compared to four to seven cycles (DFS: 89.43% versus 71.52%, p = 0.026; OS: 96.77% versus 85.46%, p = 0.007).
UNASSIGNED: The PSN panel effectively stratifies stage III colon cancer, aiding in optimized adjuvant chemotherapy duration determination.
UNASSIGNED: This study aimed to validate PSN\'s prognostic impact on stage III colon cancer, identifying candidates for optimized adjuvant chemotherapy duration.
UNASSIGNED: A retrospective analysis was conducted on a cohort of stage III colon cancer patients from April 2008 to June 2020.
UNASSIGNED: Postoperative pathological samples from stage III colon cancer patients who underwent radical surgery and postoperative adjuvant chemotherapy at Sun Yat-sen University Cancer Center were retrospectively collected. Automated digital imaging assessed PSN, categorizing risk groups. Kaplan-Meier, Cox regression, and time-dependent receiver operating characteristic analysis compared model validity.
UNASSIGNED: Significant differences in 5-year disease-free survival (DFS) and overall survival (OS) were noted among PSN-based low-, moderate-, and high-risk groups (DFS: 92.10% versus 83.62% versus 79.80%, p = 0.029; OS: 96.69% versus 93.99% versus 90.12%, p = 0.016). PSN emerged as an independent prognostic factor for DFS [hazard ratio (HR) = 1.409, 95% confidence interval (CI): 1.002-1.981, p = 0.049] and OS (HR = 1.720, 95% CI: 1.127-2.624, p = 0.012). The PSN model, incorporating perineural invasion and tumor location, displayed superior area under the curve for 5-year (0.692 versus 0.553, p = 0.020) and 10-year (0.694 versus 0.532, p = 0.006) DFS than TNM stage. In the PSN high-risk group, completing eight cycles of adjuvant chemotherapy significantly improved 5-year DFS and OS compared to four to seven cycles (DFS: 89.43% versus 71.52%, p = 0.026; OS: 96.77% versus 85.46%, p = 0.007).
UNASSIGNED: The PSN panel effectively stratifies stage III colon cancer, aiding in optimized adjuvant chemotherapy duration determination.
摘要：
■DNA倍性（P），基质分数（S），和核型(N)统称为PSN，已经证明了II期结直肠癌（CRC）的预后准确性。然而,很少有研究报道PSN小组在接受卡培他滨和奥沙利铂辅助化疗的III期结肠癌患者中的预后价值.
■本研究旨在验证PSN对III期结肠癌的预后影响，确定优化辅助化疗持续时间的候选药物。
■对2008年4月至2020年6月的III期结肠癌患者进行了回顾性分析。
■回顾性收集在中山大学肿瘤防治中心接受根治性手术和术后辅助化疗的III期结肠癌患者的术后病理样本。自动数字成像评估PSN，对风险群体进行分类。Kaplan-Meier,Cox回归,与时间相关的接收机工作特性分析比较了模型的有效性。
■在基于PSN的低，moderate-,和高危人群(DFS：92.10%对83.62%对79.80%，p=0.029；OS：96.69%对93.99%对90.12%，p=0.016)。PSN是DFS的独立预后因素[风险比（HR）=1.409，95％置信区间（CI）：1.002-1.981，p=0.049]和OS（HR=1.720，95％CI：1.127-2.624，p=0.012）。PSN模型,结合神经周浸润和肿瘤位置，5年(0.692vs.0.553,p=0.020)和10年(0.694vs.0.532,p=0.006)DFS曲线下面积高于TNM分期.在PSN高危人群中,与四至七个周期相比，完成八个周期的辅助化疗显着改善了5年DFS和OS（DFS：89.43％对71.52％，p=0.026；OS：96.77%对85.46%，p=0.007)。
■PSN小组有效地将III期结肠癌分层，有助于优化辅助化疗持续时间的确定。
■本研究旨在验证PSN对III期结肠癌的预后影响，确定优化辅助化疗持续时间的候选药物。
■对2008年4月至2020年6月的III期结肠癌患者进行了回顾性分析。
■回顾性收集在中山大学肿瘤防治中心接受根治性手术和术后辅助化疗的III期结肠癌患者的术后病理样本。自动数字成像评估PSN，对风险群体进行分类。Kaplan-Meier,Cox回归,与时间相关的接收机工作特性分析比较了模型的有效性。
■在基于PSN的低，moderate-,和高危人群(DFS：92.10%对83.62%对79.80%，p=0.029；OS：96.69%对93.99%对90.12%，p=0.016)。PSN是DFS的独立预后因素[风险比（HR）=1.409，95％置信区间（CI）：1.002-1.981，p=0.049]和OS（HR=1.720，95％CI：1.127-2.624，p=0.012）。PSN模型,结合神经周浸润和肿瘤位置，5年(0.692vs.0.553,p=0.020)和10年(0.694vs.0.532,p=0.006)DFS曲线下面积高于TNM分期.在PSN高危人群中,与四至七个周期相比，完成八个周期的辅助化疗显着改善了5年DFS和OS（DFS：89.43％对71.52％，p=0.026；OS：96.77%对85.46%，p=0.007)。
■PSN小组有效地将III期结肠癌分层，有助于优化辅助化疗持续时间的确定。
